Literature DB >> 2468053

Electrophysiologic effects of dextro- and levo-verapamil on sinus node and AV node function in humans.

H Echizen1, M Manz, M Eichelbaum.   

Abstract

The electrophysiologic effects of dextro (d)- and levo (l)-verapamil on sinoatrial (SA) and atrioventricular (AV) node function were studied in ten patients undergoing electrophysiologic evaluation of their supraventricular tachyarrhythmias. Both isomers elicited a significant prolongation of sinus node recovery time (SNRT) and AH interval. No difference between d- and l-verapamil regarding the magnitude of the effects were observed. However, 50 mg d-verapamil was required to elicit the same electrophysiologic effects as 5 mg l-verapamil. The d- and l-verapamil plasma concentrations associated with the maximum effect on AH interval and SNRT showed a more than 20-fold difference (d: 380 ng/ml; l: 19 ng/ml). These data demonstrate that both verapamil isomers possess qualitatively similar slow channel blocking effects on the SA and AV node in humans, but the l isomer is 20 times more potent than the d isomer.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2468053     DOI: 10.1097/00005344-198811000-00007

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  13 in total

1.  Field and action potential recordings in heart slices: correlation with established in vitro and in vivo models.

Authors:  Herbert M Himmel; Alexandra Bussek; Michael Hoffmann; Rolf Beckmann; Horst Lohmann; Matthias Schmidt; Erich Wettwer
Journal:  Br J Pharmacol       Date:  2012-05       Impact factor: 8.739

Review 2.  Therapeutic drug monitoring of antiarrhythmic drugs.

Authors:  Gesche Jürgens; Niels A Graudal; Jens P Kampmann
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

Review 3.  Bioequivalence of chiral drugs. Stereospecific versus non-stereospecific methods.

Authors:  R Mehvar; F Jamali
Journal:  Clin Pharmacokinet       Date:  1997-08       Impact factor: 6.447

4.  Cardiovascular effects of (R)- and (S)-verapamil and racemic verapamil in humans: a placebo-controlled study.

Authors:  Dagmar Busse; Silke Templin; Gerd Mikus; Matthias Schwab; Ute Hofmann; Michel Eichelbaum; Kari T Kivistö
Journal:  Eur J Clin Pharmacol       Date:  2006-07-04       Impact factor: 2.953

5.  Enantioselective kinetics of verapamil and norverapamil in isolated perfused rat livers.

Authors:  R Mehvar; J M Reynolds; M A Robinson; J A Longstreth
Journal:  Pharm Res       Date:  1994-12       Impact factor: 4.200

6.  Effects of verapamil enantiomers and major metabolites on the cytotoxicity of vincristine and daunomycin in human lymphoma cell lines.

Authors:  K Häussermann; B Benz; V Gekeler; K Schumacher; M Eichelbaum
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

7.  Mephenytoin stereoselective elimination in the rat: III. Stereoselective time course of induction during chronic hepatic portal vein administration.

Authors:  S H Akrawi; P J Wedlund
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1990 Jul-Sep       Impact factor: 2.441

8.  Gut wall metabolism of verapamil in older people: effects of rifampicin-mediated enzyme induction.

Authors:  M F Fromm; K Dilger; D Busse; H K Kroemer; M Eichelbaum; U Klotz
Journal:  Br J Clin Pharmacol       Date:  1998-03       Impact factor: 4.335

Review 9.  Grapefruit juice-drug interactions.

Authors:  D G Bailey; J Malcolm; O Arnold; J D Spence
Journal:  Br J Clin Pharmacol       Date:  1998-08       Impact factor: 4.335

10.  Studies of verapamil binding to human serum albumin by high-performance affinity chromatography.

Authors:  Rangan Mallik; Michelle J Yoo; Sike Chen; David S Hage
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2008-10-21       Impact factor: 3.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.